| Document |
Document Title |
|
WO/2003/102045A1 |
The present invention provides novel hybrid polymer optical alignment layers for inducing alignment of a liquid crystal medium. Hybrid polymers of this invention are prepared from at least one component selected from the group consisting...
|
|
WO/2003/101440A1 |
The invention relates to the use of 1-phenyl-3-dimethylamino-propane compounds for producing a drug for treating urinary urgency or urinary incontinence and to corresponding drugs and methods for treating urinary urgency or urinary incon...
|
|
WO/2003/101931A2 |
The invention disclosed in this application relates to an improved process for the preparation of compounds of formula (I): R1R2NCH2CH2CH2CH(OR3)2; wherein, R1 = R2 = C1-C16 alkyl; C3-C7 cycloalkyl; R1 = C1-C16 alkyl; R2 = C3-C7 cycloalk...
|
|
WO/2003/101932A2 |
A compound of Formula (IA) or Formula (IB) wherein R¿1?, R¿2?, R¿3?, R¿4?, R¿5?, R¿6?, R¿7?, and R¿8? are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds,...
|
|
WO/2003/099192A2 |
The present invention relates to biphenylyl derivatives, processes for their production, their uses and pharmaceutical compositions containing them.
|
|
WO/2003/099764A1 |
The invention provides novel β2 adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated β2 adrenergic recept...
|
|
WO/2003/099769A1 |
The present invention is directed to selective LXR modulators, small molecule compounds corresponding to Formula I and is further directed to a process of treating a condition in a mammal that is modulated by LXR using a therapeutically ...
|
|
WO/2003/099776A1 |
The compounds of the invention are represented by the following general structure (I) or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or i...
|
|
WO/2003/099273A1 |
This invention relates to a new pharmaceutically useful compound which is a stoichiometrically 1:1 adduct of tramadol hydrochloride and topiramate, and to the manufacture and use thereof.
|
|
WO/2003/097582A2 |
Benzonitrites and benzimidates represent important intermediates and starting materials, which are typically not commercially available. The present invention discloses a facile synthesis for 2,4-dihydroxybenzonitrile, and ethers and die...
|
|
WO/2003/097573A1 |
One aspect of the present invention relates to amines. A second aspect of the present invention relates to the use of the amines as inhibitors of a mammalian anandamide transporter. The compounds of the present invention will also find u...
|
|
WO/2003/097575A2 |
The invention provides novel amino-functionalised chalcone derivatives and analogues thereof. Use of the compounds, or compositions comprising them, as pharmaceutically active agents, in particular against bacterial and parasitic infecti...
|
|
WO/2003/097576A2 |
The invention provides novel diamino-functionalised chalcone derivatives and analogues thereof. Use of the compounds, or compositions comprising them, as pharmaceutically active agents, in particular against bacterial and parasitic infec...
|
|
WO/2003/097574A2 |
The invention provides novel alkoxyaminochalcone derivatives and analogues thereof. Use of the compounds, or compositions comprising them, as pharmaceutically active agents, in particular against bacterial and parasitic infections, is al...
|
|
WO/2003/096989A2 |
Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided....
|
|
WO/2003/097622A2 |
The present invention provides methods of preparing 2-alkylcysteine derivatives, many of which can be performed stereoselectively. The present invention also discloses a method of preparing a class of iron chelating agents related to des...
|
|
WO/2003/095416A1 |
The present invention relates to a method for preparing 2-Alkoxyphenoxyethanamines and more particularly relates to the preparation of the new chemical entity 2-Alkoxyphenoxyethylacetamides, in particular as intermediates in said method....
|
|
WO/2003/095415A2 |
The invention concerns aminated compounds bearing at least an allyl and a difluoromethyl and a method used for synthesis thereof. Said compounds comprise at least one carbon bearing: an amine function, an allyl or propargyl radical, a di...
|
|
WO/2003/093342A1 |
Mannich bases as curing agents for epoxy resins, characterized in that to prepare the Mannich base an isolated amine adduct is used obtainable by reacting a) an amine containing at least three active amine hydrogens with b) an epoxide co...
|
|
WO/2003/093219A1 |
The invention provides compounds of formula (I) and their medicinal salts: In which, R1 is H, CI or Br; R2 is selected from electron-withdrawing group of -CF3, -CN, -F, -COSO3H, -CF3SO3 and -NO2; R3 is C1-10 linear or branched alkyl, C2-...
|
|
WO/2003/091204A1 |
The present invention relates to novel compounds of formula (I), or a salt, solvate, or physiologically functional derivative thereof, to a process for their manufacture, to pharmaceutical compositions containing them, and to their use i...
|
|
WO/2003/091199A1 |
The invention relates to a method for converting a tertiary OH group of an organic compound into a tertiary CI group of said organic compound using a solvent selected from the group containing toluene, o-xylene, m-xylene, p-xylene and mi...
|
|
WO/2003/091262A1 |
New ligands, compositions, metal-ligand complexes and arrays with bridged bis-aromatic ligands are disclosed that catalyze the polymerization of monomers into polymers. These catalysts with metal centers have high performance characteris...
|
|
WO/2003/091198A1 |
Either an ionic liquid which is liquid at 25°C or an organic solution containing one or more ionic compounds is contacted with an electrode in an atmosphere having a dew point of -40°C or lower or at a reduced pressure of 76 Torr or lo...
|
|
WO/2003/087034A1 |
The invention relates to 3-aminophenol derivatives of formula (I) or to their physiologically compatible, water-soluble salts, wherein R1 is identical to a radical of formula (II) or to a radical of formula (III), and to dyes that contai...
|
|
WO/2003/084919A2 |
The invention concerns novel methods for preparing combretastatins by Wittig condensation between nitromethoxy-benzaldehyde and a trimethoxybenzyl phosphonium salt or inversely a nitromethoxybenzyl phosphonium salt with trimethoxybenzyla...
|
|
WO/2003/082205A2 |
Disclosed is a compound having the formula (I) pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and so...
|
|
WO/2003/082802A1 |
Disclosed is a compound of having the formula (II-A), pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts...
|
|
WO/2003/082805A1 |
The invention relates to a venlafaxine maleate compound, to a pharmaceutical composition comprising a venlafaxine maleate compound and a pharmaceutically acceptable excipient, to a method for treating a venlafaxine-treatable disease or c...
|
|
WO/2003/082800A1 |
The invention provides novel compounds of the Formula (I) that stimulate rates of glucose oxidation in myocardial cells wherein W, Cyc, p, , X, Z, R, K-, R, R1, R2, R3,R4, I and n are as defined for Formula (I) herein. The invention also...
|
|
WO/2003/082804A1 |
The invention relates to a venlafaxine besylate compound, preferably crystalline venlafaxine besylate, to a pharmaceutical composition comprising said venlafaxine besylate compound and at least one pharmaceutically acceptable excipient, ...
|
|
WO/2003/080557A1 |
The invention relates to substituted 4-aminocyclohexanols, to methods for producing them, to drugs containing said compounds and to the use of substituted 4-aminocyclohexanols in the production of drugs for the treatment of various indic...
|
|
WO/2003/080560A1 |
A process for the preparation of hydroxy (cycloalkane/cyclokene) phenylethyl amine of the general formula (III) comprising alkylation of its precursor amine of general formula (II) which is in turn produced by an effective reduction proc...
|
|
WO/2003/080561A1 |
The invention provides a process by which voglibose can be safely and easily prepared at a low cost&semi intermediates favorably usable in the process&semi and a process for preparation of the intermediates, specifically, inositol deriva...
|
|
WO/2003/078376A1 |
A NK1 antagonist having the formula (I), with the variables defined herein, which is useful for treating a number of disorders, including emesis, depression, anxiety and cough.
|
|
WO/2003/077874A2 |
The present invention relates to novel substituted tetrahydroisoquinoline compounds, pharmaceutical compositions containing the compounds, methods of making the compounds, and methods of using the compounds to destroy a target cell, such...
|
|
WO/2003/078380A2 |
A process is described for the preparation of (RR,SS˜2-dimethylaminomethyl-1-(3-methoxyphenyl) cyclohexanol hydrochloride (hereinafter 'tramadol hydrochloride'), which process comprises reacting a mixture of (RR,SS)- and (RS,SR)-2-dimet...
|
|
WO/2003/076397A1 |
The present invention relates to a compound formula [I] wherein R1 and R5 are each independently hydrogen, halogen, lower alkyl, etc., R2 is hydrogen or an amino protective group, x is bond,-o-o,-O-CH2-, etc., y is in which Z is bond, -0...
|
|
WO/2003/076386A2 |
Disclosed are catalysts, the catalytically active mass of which contains 22 to 40 percent by weight of oxygen-containing compounds of zirconium, calculated as ZrO2, 1 to 30 percent by weight of oxygen-containing compounds of copper, calc...
|
|
WO/2003/074469A1 |
The invention relates to novel cinnamate salts of Salmeterol, method for production and use thereof as medicaments.
|
|
WO/2003/074495A1 |
Compounds of formula (1) or a pharmaceutically acceptable salt, solvate, acid isostere, or hydrolyzable ester thereof, are disclosed. Methods of making and using the compounds are also disclosed. In particular methods for treating diseas...
|
|
WO/2003/072535A2 |
This present invention relates to prodrug compounds of the formula (Y) and pharmaceutical salts thereof: where RN, R1, R2, R3R4 and RC are defined herein, which are useful in treating Alzheimer's disease and other similar diseases.
|
|
WO/2003/070675A2 |
This invention provides a compound, or its possible salt, having the formula, wherein: Re and 'Re are OH, optionally independently etherified or esterified&semi Z is −CH2CH2− or −C(R4,R5)− , wherein R4 and R5 are independently H,...
|
|
WO/2003/067983A1 |
Surfactant compounds are of the general formula (I): R1(R2)X1CH2CH(OH)CH2(OA)nOR3 (I) where R1 is hydrocarbyl&semi R2 is hydrocarbyl&semi R2 is H or hydrocarbyl&semi X1 is a nitrogen containing group as defined, and R3 is hydrocarbyl, an...
|
|
WO/2003/066564A1 |
A process for producing (R)−3−hydroxy−3−(2−phenylethyl)hexanoic acid characterized in that racemic 3−hydroxy−3−(2−phenylethyl)hexanoic acid is optically resolved by using an optically active amine represented by the fol...
|
|
WO/2003/066570A1 |
The present invention relates to a process for the preparation of N-aryl amine and N- aryl amide compounds. Generally, the process of the present invention involves reacting a compound having a primary or secondary amino or amido group w...
|
|
WO/2003/064372A1 |
The use of a compound of formula (1) wherein X is oxygen or (CR¿11?R¿12?)¿n?; n is 0 or 1; R¿1?, R¿2?, R¿3?, R¿4?, R¿5?, R¿6?, R¿7?, R¿8?, R¿11? and R¿12? are independently selected from hydrogen, alkyl, aryl and non-aromati...
|
|
WO/2003/063790A2 |
The present invention relates to oligoesters and their use for the creation of additives. Oligoester containing additives and/or oligoesters themselves may be used for formulating pharmaceutical preparations, cosmetics or personal care p...
|
|
WO/2003/061552A2 |
Substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone, a compound of formula (1), is prepared by a novel route, which comprises reacting 3-(3,5-dimethylphenoxy)-2-hydroxypropylamine, a compound of formula (2), or its acid addi...
|
|
WO/2003/059864A2 |
Formula (I) compounds are described: Where the groups are as defined here below, and their use as medinies, particularly as serum glucose and serum lipid lowering agents. Said medicines are useful for the prophylaxis and treatment of dia...
|
